Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, random...
Project: EU-RESPONSE
Updated at: 01-11-2025
Project: EU-RESPONSE
Updated at: 01-11-2025
Project: EU-RESPONSE
Updated at: 01-11-2025
Project: EU-RESPONSE
Updated at: 01-11-2025
Project: EU-RESPONSE
Updated at: 01-11-2025
Project: EU-RESPONSE
Updated at: 01-11-2025
Project: EU-RESPONSE
Updated at: 01-11-2025
Project: EU-RESPONSE
Updated at: 01-11-2025
Project: EU-RESPONSE
Updated at: 13-08-2024
Project: EU-RESPONSE
Updated at: 28-02-2024
Project: EU-RESPONSE
Updated at: 28-02-2024
Project: EU-RESPONSE
Updated at: 28-02-2024
Project: EU-RESPONSE
Updated at: 28-02-2024
Project: EU-RESPONSE
Updated at: 28-02-2024
Project: EU-RESPONSE
Updated at: 28-02-2024
Project: EU-RESPONSE
Updated at: 28-02-2024
Project: EU-RESPONSE
Updated at: 30-10-2023
Project: EU-RESPONSE
Updated at: 30-10-2023
Project: EU-RESPONSE
Updated at: 30-10-2023
Project: EU-RESPONSE
Updated at: 30-10-2023
Project: EU-RESPONSE
Updated at: 30-10-2023
Project: EU-RESPONSE
Updated at: 30-10-2023
Project: EU-RESPONSE
Updated at: 30-10-2023
Project: EU-RESPONSE
Updated at: 30-10-2023
Project: EU-RESPONSE
Updated at: 30-10-2023